Introduction
============

Around 50% of all colorectal cancer (CRC) patients will develop liver metastases over the course of time [@B1]. Currently, only 30% of patients with colorectal liver metastases (CLM) are curable [@B2]-[@B4]. A profound molecular understanding of CLM could lead to the development of tailored therapeutic approaches to improve patient outcome.

Recent data indicate that the innate and adaptive immune systems appear to play a crucial role in the anti-tumor response against solid malignancies [@B5]. In primary CRC, the presence of tumor infiltrating T helper type 1 (Th1), cytotoxic T lymphocytes (CTLs) and memory T cells are associated with an improved disease-free survival (DFS) and overall survival (OS) [@B6]-[@B12].

This raises the question of how those T cells are activated within CLM. One likely candidate for T cell activation is type I interferon (IFN) [@B13]-[@B15]. Type I IFN is involved in the priming of T cells against tumor-associated antigens (TAAs) by professional antigen-presenting cells (APCs), as well as in the intratumoral accumulation of dendritic cells (DCs) and spontaneous cross-priming of tumor antigen-specific T cells *in vivo* [@B16]-[@B20]. Moreover, host type I IFN has been shown to be mandatory for the efficacy of chemotherapy [@B21].

In murine models, tumor-derived deoxyribonucleic acid (DNA), incorporated by DCs, is capable of activating the stimulator of interferon genes (STING) pathway, resulting in type I IFN production [@B22], [@B23]. The STING pathway plays a fundamental role in the process of recognizing damage-associated molecular patterns (DAMPs), such as tumor-derived DNA. STING is an adapter protein, which gets activated by cyclic dinucleotides (CDNs), generated by cyclic guanosine monophosphate‑adenosine monophosphate (GMP-AMP) synthase (cGAS), which in turn is directly activated by cytosolic DNA [@B24]-[@B26]. Strikingly, radiation-induced type I IFN‑dependent anti-tumor immunity also depends on the functional DNA-sensing STING pathway [@B27]. Moreover, DAMPs such as double-stranded ribonucleic acid (dsRNA) can lead to activation of the protein kinase R (PKR) following an endoplasmic reticulum (ER) stress response, mediated by the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α), which results in a calreticulin (CALR) mediated immunogenic cell death (ICD) [@B28].

In primary CRC, a type I and type II IFN-driven tumor microenvironment (TME) is associated with a Th1 immune reaction and an increased DFS [@B29]. Furthermore, mutated kirsten rat sarcoma viral oncogene homolog (KRAS) might abolish such a potential protective immune response by blunting an effective type I IFN response [@B30].

In this work, we evaluated this correlation in the clinical setting of CLM. Based on the pre-clinical data, we hypothesized that DNA damage would correlate with an increased type I IFN response and subsequently with a high infiltration of tumor-ablative immune cells, leading to an improved prognosis in CLM.

In contrary to the predictions from pre-clinical data, DNA damage was inversely correlated with ICD and negatively associated with pathological response and clinical prognosis.

Methods
=======

Patient collective
------------------

A total of 70 patients with resectable or borderline resectable colorectal liver metastases (CLM), who underwent 3 cycles of neoadjuvant and adjuvant bevacizumab-based chemotherapy, following liver resection with a curative intent at the Department of Surgery of the Medical University of Vienna between 2005 and 2011, were retrospectively enrolled in this study. Of these, 33 were appropriate for our study (**Figure [S1](#SM0){ref-type="supplementary-material"}**). Patient characteristics were available from a prospectively maintained database (**Table [1](#T1){ref-type="table"}**). Median follow-up time, 9 years (95% CI 7.56-10.45), was calculated according to the reversed Kaplan-Meier method [@B31]. This study was conducted according to the reporting recommendations for tumor marker prognostic studies (REMARK) [@B32].

Therapy application
-------------------

To achieve or improve resectability of CLM, all patients received a neoadjuvant treatment. Patients receiving chemotherapy in combination with the monoclonal antibody (mAb) bevacizumab, targeting the vascular endothelial growth factor-A (VEGF-A), obtained one of the following regimens:

XELOX + bevacizumab: 21-day treatment cycle comprised the intravenous (IV) administration of bevacizumab 7.5 mg/kg over 30 min, oxaliplatin 130 mg/m^2^ over 2 h and oral capecitabine 850 mg/m^2^ twice daily on days 1 to 14.

XELIRI + bevacizumab: 21-day treatment cycle comprised the IV administration of bevacizumab 7.5 mg/kg over 30 min, irinotecan 250 mg/m^2^ and oral capecitabine 1000 mg/m^2^ twice daily on days 1 to 14.

FOLFOX + bevacizumab: 14-day treatment cycle comprised the IV administration of bevacizumab 5 mg/kg over 15 min, oxaliplatin 85 mg/m^2^ over 2 h, folinic acid 400 mg/m^2^ over 2 h concurrent with oxaliplatin, a bolus of fluorouracil 400 mg/m^2^ and fluorouracil 2400 mg/m^2^ over 48 h.

FOLFIRI + bevacizumab: 14-day treatment cycle comprised the IV administration of bevacizumab 5 mg/kg over 15 min, irinotecan 180 mg/m^2^ over 90 min, folinic acid 400 mg/m^2^ over 2 h concurrent with irinotecan, a bolus of fluorouracil 400 mg/m^2^ and fluorouracil 2400 mg/m^2^ over 46 h.

TOMOX + bevacizumab: 21-day treatment cycle comprised the IV administration of bevacizumab 7.5 mg/kg over 30 min, raltitrexed 3 mg/m^2^ over 15 min and oxaliplatin 130 mg/m^2^ over 2 h.

Raltitrexed + irinotecan + bevacizumab: 21-day treatment cycle comprised the IV administration of bevacizumab 7.5 mg/kg over 30 min, raltitrexed 3 mg/m^2^ over 15 min and irinotecan 350 mg/m^2^ over 90 min.

Irinotecan + bevacizumab: 21-day treatment cycle comprised the IV administration of bevacizumab 7.5 mg/kg over 30 min and irinotecan 350 mg/m^2^ over 90 min.

For patients who received chemotherapy in combination with the mAb cetuximab, targeting the epidermal growth factor receptor (EGFR), obtained the following regimen:

FOLFIRI + cetuximab: 28-day treatment cycle comprised the IV administration of cetuximab, starting with a loading dose of 400 mg/m^2^ over 2 h, followed by 250 mg/m^2^ over 1 h every week, irinotecan 180 mg/m^2^ over 90 min, folinic acid 400 mg/m^2^ over 2 h concurrent with irinotecan, a bolus of fluorouracil 400 mg/m^2^ and fluorouracil 2400 mg/m^2^ over 48 h, given on days 1 and 15.

For patients receiving chemotherapy alone, they obtained either XELOX as described above or oral capecitabine 1250 mg/m^2^ twice daily for 2 weeks in a 21-day treatment cycle.

The type of regimen and dose alteration was based on the decision of the local multidisciplinary tumor board team. The different chemotherapy regimens were preferentially given in combination with bevacizumab as long as there were no contraindications, such as history of gastrointestinal perforation, fistulas, wound healing complications, challenging hypertension, proteinuria, arterial or venous thromboembolic events, bleedings, congestive cardiac failure, current infection or neutropenia.

Evaluation of radiographic therapy response
-------------------------------------------

Radiographic therapy response was determined by an expert radiologist (D.T.) of the Department of Radiology and Nuclear Medicine of the Medical University of Vienna, who was blinded to clinical data.

Change of metastases diameter between pre- and post‑neoadjuvant treatment was evaluated by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). Metastases were classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), according to the response evaluation criteria in solid tumors (RECIST) 1.1 [@B33]. Briefly, CR (vanishing of all lesions), PR (decrease in ≥30% size), SD (decrease in \<30% size) and PD (increase in ≥20% size). Patients were considered as good (CR, PR) or poor (SD, PD) responders.

Evaluation of radiomorphologic therapy response
-----------------------------------------------

Radiomorphologic therapy response was determined by an expert radiologist (D.T.) of the Department of Radiology and Nuclear Medicine of the Medical University of Vienna, who was blinded to clinical data.

Change of metastases morphology between pre- and post‑neoadjuvant treatment was evaluated by contrast-enhanced CT scans according to the novel morphological response criteria [@B34]-[@B36]. Briefly, target lesions were evaluated and grouped according to their overall attenuation (heterogeneous, mixed or homogeneous/hypoattenuating), tumor-liver interface (defined, variable or sharp) and peripheral rim enhancement (may be present, if primarily present, incompletely resolved or if primarily present, completely resolved). Group 1 was classified by a homogeneous overall attenuation, a sharply defined tumor-liver interface and a completely resolved peripheral rim enhancement. Group 3 was characterized by a heterogeneous overall attenuation, a poorly defined tumor-liver interface and absence of a peripheral rim enhancement or if primarily present, no resolution. Group 2 was classified by an intermediate morphology, which could not be scored as group 1 or 3. Optimal response (OR) was defined by a change from group 3 or 2 to group 1, partial response (PR) was considered for a change from group 3 to group 2 and absent response (AR) if there was no group change or progression from group 2 to group 3. Patients were considered as good (OR, PR) or poor (AR) responders.

Evaluation of pathologic therapy response
-----------------------------------------

An expert hepatobiliary pathologist (J.S.) of the Department of Pathology of the Medical University of Vienna, who was blinded to clinical data, assessed the histologic characteristics of hematoxylin and eosin (H&E) stained specimens.

Pathologic therapy response was semi‑quantitatively assessed by the amount of vital tumor cells, as a percentage relative to all tumor cells. Areas of usual necrosis (UN), indicating an insufficient treatment effect, were considered as part of vital tumor cells. However, infarct-like necrosis (ILN), characterizing a therapeutic response to chemotherapy, was considered as non-vital tumor cells [@B37]. On this basis, we allocated each specimen into one quartile (≥75%, 50-75%, 25-49% or \<25% viable tumor cells).

Evaluation of histologic therapy response
-----------------------------------------

An expert hepatobiliary pathologist (J.S.) of the Department of Pathology of the Medical University of Vienna, who was blinded to clinical data, assessed the histologic characteristics of H&E stained specimens.

Histologic therapy response was assessed semi-quantitatively according to the tumor regression grading (TRG) [@B38]. Briefly, TRG1 was classified by the absence of tumor cells replaced by extensive fibrosis. TRG2 represented seldom remaining tumor cells dispersed through extensive fibrosis. TRG3 characterized more remaining tumor cells dispersed through predominant fibrosis. TRG4 described large amount of vital tumor cells predominating over fibrosis. TRG5 contained mostly vital tumor cells without any fibrosis.

Moreover, we incorporated the consideration of ILN into a modified TRG (mTRG) [@B37].

For the declaration of hepatic steatosis, a cut-off of 5% steatotic cells of patient matched normal liver tissue was used [@B39].

Analysis of mutation status
---------------------------

Kirsten rat sarcoma viral oncogene homolog (KRAS) and V‑raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation status of CLM was determined as previously described [@B40]. Briefly, genomic DNA was extracted from tissue blocks and exon 2 and 3 of the KRAS gene and exon 15 of the BRAF gene were polymerase chain reaction (PCR) amplified with AmpliTaq Gold® DNA polymerase (Applied Biosystems, Fisher Scientific, Vienna, Austria) and corresponding oligonucleotide primers (**Table [S1](#SM0){ref-type="supplementary-material"}**). Excess of primers and deoxynucleotides (dNTPs) was removed by incubation of 5 µL PCR product with 2.5 U exonuclease I (GE Healthcare Life Sciences, Vienna, Austria) and 2.5 U shrimp alkaline phosphatase (SAP; GE Healthcare Life Sciences) at 37°C for 1 h. Enzymes were further heat inactivated at 70°C for 15 min, following sequence analysis with 1-2 µL of the purified PCR product and 4 pmol primers using the BigDye™ Terminator Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer\'s instructions. Excess of BigDye™ Terminator nucleotides was removed by centrifugation with Centri-Sep™ Spin Columns (Invitrogen, Fisher Scientific, Vienna, Austria). Separation and analysis of the sequencing reaction products were performed with an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems) according to manufacturer\'s protocol.

Analysis of mismatch repair status
----------------------------------

Mismatch repair (MMR) status, proficient or deficient, was determined by immunohistochemistry (IHC) [@B41], [@B42]. For this purpose, MutL homolog 1 (MLH1; Ventana Medical Systems Inc.) and MutS protein homolog 2 (MSH2; Cell Marque, Rocklin, CA, USA) were stained by an automated IHC slide staining BenchMark ULTRA system (Ventana Medical Systems Inc.) according to manufacturer\'s protocol (**Table [S2](#SM0){ref-type="supplementary-material"}**). Briefly, samples were deparaffinized following heat-induced epitope retrieval (HIER) at 95°C for 52 min at pH 8 (ready-to-use solution). Antibody binding was visualized using the ultraView Universal DAB Detection Kit (Ventana Medical Systems Inc.). Slides were counterstained with hematoxylin (Ventana Medical Systems Inc.) and sealed with coverslips. All samples were evaluated by an expert hepatobiliary pathologist (J.S.) of the Department of Pathology of the Medical University of Vienna, who was blinded to clinical data. Tumor showing loss of MLH1 and MSH2 expression were classified as mismatch repair deficient. Matched nuclear staining of lymphocytes served as an internal positive control.

Immunohistochemistry
--------------------

Formalin-fixed paraffin-embedded (FFPE) tissue of CLM was obtained from the Department of Pathology of the Medical University of Vienna. Consecutive 1 µm thick slices were cut from FFPE tumor tissue. Paraffin wax was melted at 60°C for 2 h and, subsequently, slides were deparaffinized in xylene (Fisher Scientific, Pittsburgh, PA, USA) and rehydrated in declining dilutions of ethanol. For HIER, slides were incubated in 10 mM sodium citrate (Sigma-Aldrich, St. Louis, MO, USA) containing 0.05% Tween 20 (Sigma-Aldrich) at pH 6.0 or in 10 mM tris(hydroxymethyl)aminomethane (Merck Millipore, Darmstadt, HE, DE) and 1 mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich) containing 0.05% Tween 20 at pH 9.0 and heated up in pressure cooker until 121°C. Consequently, slides were cooled down to room temperature (RT) and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich) in phosphate-buffered saline (PBS) for 5 min at RT. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide (Merck Millipore) in PBS for 10 min at RT in the dark. Afterwards, slides were incubated with 5% normal horse serum in PBS (VECTASTAIN Elite ABC HRP Kit; Vector Laboratories, Burlingame, CA, USA) for 20 min at RT. Primary antibodies (**Table [S2](#SM0){ref-type="supplementary-material"}**) were incubated for 1 hr at RT in a humidified chamber. Afterwards biotinylated horse anti-mouse IgG/anti-rabbit IgG secondary antibody (VECTASTAIN Elite ABC HRP Kit; Vector Laboratories) was applied for 30 min at RT, following incubation with the AB reagent (VECTASTAIN Elite ABC HRP Kit; Vector Laboratories) for 30 min at RT in the dark. Color development was conducted with the DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories). Slides were counterstained with Mayer\'s hemalum solution (Merck Millipore), dehydrated in ascending dilutions of ethanol, incubated in n‑Butyl acetate (Fisher Scientific) for 2 min at RT, mounted with Entellan (Merck Millipore) and sealed with coverslips.

CD3, CD8, CD45RO, GBP1, Ki-67 and MxA were stained by an automated immunohistochemistry staining Benchmark XT system (Ventana Medical Systems Inc., Tucson, AZ, USA) using the reagents and steps according to the manufacturer\'s protocol. Briefly, following deparaffinization, HIER was performed at 42°C for 30 min at pH 9 (ready-to-use solution). Antibody binding was visualized using the ultraView Universal DAB Detection Kit (Ventana Medical Systems Inc.). Slides were counterstained with Mayer\'s hematoxylin (Zymed Laboratories Inc., San Fransisco, CA, USA) and sealed with coverslips.

Whole-slide tissue cell quantification
--------------------------------------

Microscopic images of whole-slide tissue sections were automatically acquired with TissueFAXS scanning systems (TissueGnostics GmbH, VIE, AUT), using a Zeiss Observer Z1 microscope (Carl Zeiss AG, Oberkochen, BW, GER) equipped with a SCAN IM 12-slide scanning stage (Marzhauser Wetzlar GmbH & Co. KG, Wetzlar, HE, GER) and a Baumer HXG40c camera (Baumer Group, Frauenfeld, TG, CHE), operated by TissueFAXS 4.2 Slides software (TissueGnostics). Acquisition was performed with an EC Plan-Neofluar 20x/0.5 M27 objective (Zeiss). Acquired imaging data was analyzed with the image analysis software StrataQuest 5.0.1.264 (TissueGnostics).

Two different regions were analyzed within the CLM: (i) tumor (TU) and (ii) invasive margin (IM; tumor/adjacent liver border). For this purpose, the clear distinguishable tumor area was marked manually and a standardized invasive margin area, with an exact width of 500 µm on each side of the tumor/adjacent liver border, was created automatically by the analysis software (**Figure [S2](#SM0){ref-type="supplementary-material"}**).

For absolute cell quantification a (i) nuclei mask was programmed, which detects all single cells on the basis of the cell nuclei staining and morphology. This nuclei mask was further used for the generation of an (ii) antibody detection mask, identifying the antibody specific staining pattern (membrane, cytoplasmic or nucleus) of the differently used antibodies (**Figure [S3](#SM0){ref-type="supplementary-material"}**).

Values are given as percentages of nuclei and antibody specific-stained single cells out of all nuclei-stained single cells at each region of interest. All computerized evaluations were visually crosschecked for reliability.

Statistics
----------

Recurrence-free survival (RFS) was the primary endpoint of this study and defined as the time between surgery of CLM and observation of the first recurrence (local or distant) or cancer-related death. Overall survival (OS), defined as the time between resection of CLM and cancer-related death, radiographic therapy response and pathologic therapy response were secondary endpoints. If a patient had neither a recurrence nor a cancer-related death, RFS or OS was censored at the date of the last follow-up or known to be alive.

All statistical analyses were computed with R version 3.4.1 [@B43]. Percentage of marker panel events were log~2~ transformed to achieve approximate normal distributions. Missing IHC (up to 24% for CD3 values) and clinical data (radiographic therapy response, radiomorphologic therapy response, histology, pathologic therapy response, histologic therapy response, and modified histologic therapy response) were imputed with values estimated by the predictive mean matching method using R-package "mice" (version 2.30; table without imputed values is shown in **Table [S3](#SM0){ref-type="supplementary-material"}**).

Principal component analysis (PCA), correlation matrix plots and Pearson\'s correlation coefficients for IM and TU were calculated with intrinsic R commands and R‑package "corrplot" (version 0.77). P-values of the "corrplot" were corrected according to the false discovery rate (FDR) [@B44].

Univariate Cox regression analyses were calculated with R commands. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were plotted with R-package "forestplot" (version 1.8). Prognostics models were computed with an adaptive elastic net approach for censored data using the R-package "hdnom" (version 4.8.9000) and are illustrated by nomograms. For this purpose, the "hdcox.aenet" command with a 4-fold internal cross-validation and lambda selection based on the one standard error cut-off method ("lambda.1se"), which gives the most regularized model in which the error is within one standard error of the minimum mean cross‑validated error, was used. The final prognostic models were further bootstrap-based validated at several time points and results are depicted by corresponding plots. The model-predictor was further dichotomized into a high‑risk and low-risk group to illustrate the impact of each final model on clinical outcome, which is illustrated by Kaplan-Meier survival estimates. As the survival estimates are originated from the multivariable models, no censored patients are included.

To predict radiographic and pathologic therapy response with the marker panel, least absolute shrinkage and selection operator (LASSO) logistic regression models were generated with the R-package "glmnet" (version 2.0-10), internally cross-validated and regularized as described above. For each outcome (radiographic or pathologic) the model with the best prediction performance, based on the area under the receiver operating characteristic (ROC) curve (AUC), was selected. Boxplots of the corresponding model-values are illustrated next to the AUC plots.

The Venn diagram was plotted using R-package "VennDiagram" (version 1.6.17). All p‑values were 2-sided and considered as statistically significant if \<0.05.

Results
=======

Marker panel events at the invasive margin and tumor area are correlated
------------------------------------------------------------------------

We determined proteins involved in DNA damage (γH2AX), RNA and DNA sensors (RIG-I, DDX41, cGAS, STING), ER stress response (p-PKR, p‑eIF2α, CALR), type I and type II IFN-induced proteins (MxA and GBP1 respectively) and tumor-infiltrating immune cells, such as activated DCs (CD208) and T cells (CD3, CD8, CD45RO) in patients with CLM by the use of a quantitative immunohistochemistry approach (**Figure [1](#F1){ref-type="fig"}A**).

To evaluate the data explaining variance of our marker panel, we initially performed a principal component analysis (PCA). Strikingly, nearly all vectors, indicating the impact of each marker on the PCs, pointed in the same direction within the PC1 (**Figure [1](#F1){ref-type="fig"}B**). This implies that the biological raised question in this work accounts for the highest variance in the data (i.e., PC1). Moreover, IM and TU vectors of each individual marker were approximately overlapping, indicating an association between each other. The latter observation was further confirmed by a correlation analysis of the marker panel values at the IM and TU (**Figure [1](#F1){ref-type="fig"}C**). Taking all these facts into account, we conducted all further analysis only with the marker panel values at the IM.

DNA damage and ER stress response are inversely associated with recurrence-free survival
----------------------------------------------------------------------------------------

We assessed the association of our marker panel with recurrence-free survival (RFS). We first conducted a univariate Cox regression analysis (**Figure [2](#F2){ref-type="fig"}A**). Interestingly, the amount of DNA damage, represented by γH2AX, was associated with a shorter RFS (HR 1.32, 95% CI 1.04-1.69, p=0.023). In contrast, ER stress response, characterized by the exposure of calreticulin (CALR), was linked with a longer RFS (HR 0.83, 95% CI 0.69-0.98, p=0.03). In this line, cytotoxic T cells (CTLs; CD8) were also related with a longer RFS (HR 0.67, 95% CI 0.50-0.89, p=0.007).

Furthermore, we conducted a univariate Cox regression analysis for the clinical characteristics (**Figure [2](#F2){ref-type="fig"}B**). The clinical characteristics that contributed with statistical significance to RFS were distribution of metastases (HR 0.31, 95% CI 0.15-0.62, p=0.001), number of metastases (HR 1.20, 95% CI 1.07-1.36, p=0.003), tumor vitality (HR 1.02, 95% CI 1.01‑1.04, p=0.004), modified histologic response (HR 2.68, 95% CI 1.24-5.80, p=0.013) and KRAS status (HR 2.32, 95% CI 1.04-5.15, p=0.039).

Additionally, we assessed a multivariable analysis for RFS by combining the marker panel and clinical variables. For this intent, we built an internally cross-validated adaptive elastic‑net model (**Figure [2](#F2){ref-type="fig"}C**), which was further bootstrap-validated at certain time-points (**Figure [2](#F2){ref-type="fig"}D**). The model contributing statistical significance to the 5-year RFS probability consisted of the markers γH2AX, CALR, CD8, GBP1, p-PKR and CD208, as well as the clinical variables metastases distribution, KRAS status, modified histologic therapy response, timing of metastases, histologic therapy response and histology. Apart from the CLM distribution, γH2AX had the strongest association (negative) with RFS.

The prognostic power of the model for RFS revealed a stable median AUC of \~0.8 over time. On the basis of the statistically significant model for RFS, patients were further dichotomized into high-risk and low-risk groups. Comparison between the two different groups revealed a statistically significant different RFS probability (p\<0.001; **Figure [2](#F2){ref-type="fig"}E**).

DNA damage and DNA sensor DDX41 are negatively associated with overall survival
-------------------------------------------------------------------------------

To investigate the association impact of our marker panel with OS we conducted a univariate Cox regression analysis (**Figure [3](#F3){ref-type="fig"}A**). The amount of γH2AX, the DNA sensor DDX41, as well as p-PKR were negatively associated with OS (HR 1.61, 95% CI 1.23-2.11, p\<0.001; HR 1.22, 95% CI 1.04-1.44, p=0.017 and HR 1.33 95% CI 1.07-1.64, p=0.009; respectively).

With respect to the clinical characteristics and their impact on OS, a univariate Cox regression analysis revealed that metastases distribution (HR 0.37, 95% CI 0.18-0.76, p=0.007), number of metastases (HR 1.15, 95% CI 1.01-1.30, p=0.035), radiographic therapy response (HR 3.27, 95% CI 1.38-7.71, p=0.007) and KRAS status (HR 2.65, 95% CI 1.10-6.40, p=0.03) had a statistically significant association with OS (Fig. [3](#F3){ref-type="fig"}B).

Next, we performed an adaptive elastic‑net model for the marker panel and the clinical characteristics together, as described above. The analysis revealed a model, which included the markers γH2AX, CD8 and DDX41, as well as the clinical variables such as metastases distribution, radiographic therapy response and KRAS status, which all together contributed statistical significance to the 5-year OS probability (**Figure [3](#F3){ref-type="fig"}C**). Again, γH2AX was the strongest molecular parameter, which had a negative impact on OS. The model was further bootstrap-validated over time, which revealed a stable median AUC of \~0.9 (**Figure [3](#F3){ref-type="fig"}D**). On the basis of the statistically significant model, patients were further dichotomized into high-risk and low-risk groups, which revealed a significant different OS probability between the two groups (p\<0.001; **Figure [3](#F3){ref-type="fig"}E**).

ER stress response correlates with a functional type II IFN system and cytotoxic T cell infiltration
----------------------------------------------------------------------------------------------------

In order to investigate the biological relationship between the different markers of our marker panel, we generated a correlogram (**Figure [4](#F4){ref-type="fig"}**). Strikingly, ER stress response (CALR) was positively correlated with a functional type II IFN system, represented by the expression of GBP1 (r=0.67, FDR\<0.001), CTLs (CD8; r=0.54, FDR=0.015) and the DNA sensors cGAS (r=0.48, FDR=0.005). A functional type II IFN system (GBP1) was further positively correlated with memory T cells (CD45RO; r=0.46, FDR=0.04) and the DNA sensor cGAS (r=0.47, FDR=0.012). Pan T cells (CD3) were positively correlated with cytotoxic T cells (CD8; r=0.56, FDR=0.001). The RNA sensor RIG-I showed a positive correlation with a higher cell proliferation index, represented by Ki‑67 (r=0.39, FDR=0.047).

DNA sensors DDX41, STING and p-PKR predict radiographic therapy response
------------------------------------------------------------------------

Next, we investigated the association of our marker panel with radiographic as well as radiomorphologic therapy response (**Figure [S4](#SM0){ref-type="supplementary-material"}A-C**). Patients were dichotomized into good responder (CR, PR and OR, PR, respectively) and poor responder (SD, PD and AR, respectively).

We conducted a univariate analysis between good and poor responders, which revealed the DNA sensor DDX41 as the only statistically significant marker associated with radiographic therapy response (p=0.013; **Figure [5](#F5){ref-type="fig"}A**). With respect to radiomorphologic response, there was a statistically significant association seen between γH2AX and good or poor response (p=0.043; **Figure [S5](#SM0){ref-type="supplementary-material"}A**).

We further generated a multivariable logistic regression model, using a LASSO approach. The statistically significant model, which predicted radiographic therapy response, was comprised of the markers DDX41, STING and p-PKR, (AUC=0.785, p=0.002; **Figure [5](#F5){ref-type="fig"}B**). The coefficients of DDX41 and p-PKR comparted a negative impact to STING, which was positively associated with radiographic therapy response (**Figure [5](#F5){ref-type="fig"}C**). Of note, within a multivariable logistic regression model for radiomorphologic response, γH2AX remained the only statistically significant associated marker, which had a negative impact on treatment response (AUC=0.712, p=0.022; **Figure [5](#F5){ref-type="fig"}B-C**).

DNA damage, DNA sensors DDX41 and cGAS, ER stress, DCs and memory T cells predict pathologic therapy response
-------------------------------------------------------------------------------------------------------------

We examined the association of our marker panel with pathologic, histologic as well as with modified histologic therapy response (**Figure [S4](#SM0){ref-type="supplementary-material"}D-E**). Patients were dichotomized into good responders (0-25% viable, TGR 1-3 and mTRG 1-3, respectively) and poor responders (≥25% viable, TRG 4-5 and mTRG 4-5, respectively).

A univariate analysis between good and poor responder revealed a statistically significant correlation between cGAS and pathologic therapy response, as well as between p‑eIF2α and CD208 and modified histologic therapy response (p=0.014, p=0.016 and p=0.035 respectively; **Figure [5](#F5){ref-type="fig"}D** and **Figure [S6](#SM0){ref-type="supplementary-material"}D**). Regarding the evaluation of histologic therapy response, there was no association between any marker and good or poor response (**Figure [S6](#SM0){ref-type="supplementary-material"}A**).

Next, we performed a multivariable logistic regression analysis, using a LASSO approach. The model contributing statistical significance to the prediction of pathologic therapy response comprised the markers γH2AX, DDX41, cGAS, p‑eIF2α, CD208 and CD45RO (AUC=0.944, p\<0.001; **Figure [5](#F5){ref-type="fig"}E**). Within this model the individual coefficients of γH2AX, DDX41, p‑eIF2α, CD208 and CD45RO had a negative impact compared to cGAS, which was positively associated with pathologic therapy response (**Figure [5](#F5){ref-type="fig"}F**).

In contrast, a multivariable evaluation of histologic therapy response revealed no association between any marker and response to therapy (**Figure [S6](#SM0){ref-type="supplementary-material"}B-C**). However, multivariable analysis for modified histologic therapy response revealed a statistically significant model, which comprised the markers cGAS, p‑eIF2α, MxA, GBP1 and CD208 (AUC=0.926, p\<0.001; **Figure [S6](#SM0){ref-type="supplementary-material"}E**). The individual coefficients of cGAS and GBP1 were positively associated with modified histologic response compared to p‑eIF2α, MxA and CD208, which were negatively associated (**Figure [S6](#SM0){ref-type="supplementary-material"}F**).

DNA damage, ER stress response and DNA sensor DDX41 are associated with therapy response and clinical outcome
-------------------------------------------------------------------------------------------------------------

We summarized the contribution of each individual marker to one of the two prognostics (RFS and OS) and predictive (radiographic and pathologic therapy response) models in a Venn diagram (**Figure [6](#F6){ref-type="fig"}**). This summary highlights the role of DNA damage (γH2AX), ER stress response (CALR) and the DNA sensor DDX41, which contributed the most to the preoperative evaluation of radiographic therapy response, RFS and postoperative evaluation of pathologic therapy response.

Discussion
==========

Recent murine data gave evidence that the initiation of a so called *bona fide* ICD depends on the release of danger signals, such as DNA damage [@B45]-[@B48], which gets sensed in part by the cGAS-STING pathway [@B26], [@B49], [@B50], following the induction of a type I IFN response [@B15], [@B18], which links the innate and adaptive immune system and thereby supports an anti‑tumor immune response.

In contrast to murine data, we found in our clinical dataset that DNA damage (γH2AX) is negatively associated with RFS, OS and pathologic therapy response. DNA damage has an inverse impact on the clinical outcome compared to CTL (CD8) infiltration, as well as ER stress response (CALR). Correspondingly, the DNA sensor DDX41 is associated with a shorter OS, as well as poor radiographic and pathologic therapy response. The negative prognostic and predictive role of DNA damage can be explained by its dual role, which on one hand promotes an ICD, while on the other hand facilitates the assembly of DNA repair proteins, which favors tumor cell survival [@B51], [@B52]. In line with the latter role, a recent study demonstrated that the expression of DNA damage at the time of diagnosis predicts poor treatment response to chemotherapy in breast cancer patients [@B53]. Moreover, DNA damage has been reported as an inducer of tumorigenicity and stemness in patient-derived glioma cells [@B54]. The negative impact of γH2AX on RFS and OS suggests that patients with CLM, which develop high amounts of DNA damage, render a "high-risk" group of patients throughout the course of the disease.

The DNA sensor DDX41, which is upstream of the STING pathway, also has a dual role in tumorigenesis [@B55]. On one hand, DDX41 serves as a tumor suppressor in hematological malignances, while in solid tumors DDX41 has been reported as a tumor promotor. Here, we strengthen DDX41 as a negative prognosticator for OS and negative predictor for radiographic and pathologic therapy response.

Our findings indicate that STING and cGAS induction positively correlate with response to therapy, but this induction is not associated with activation of the type I IFN pathway (MxA) or DNA damage, as the later negatively correlates with therapy response. However, DNA damage appears to mediate a stress response, as observed by the negative impact of up-regulated p‑PKR and p-eIF2α. This suggests that part of the ER stress response is involved in the negative impact of DNA damage on therapeutic unresponsiveness.

The differences seen in our clinical observations compared to murine studies, which describe an immunostimulatory effect of DNA damage, might be explained by the fact that DNA damage was rather shortly induced before the analysis [@B27]. In contrast, in our clinical setting, neoadjuvant therapy was usually finished four weeks before liver resection. Thus, we propose that the protein expression pattern observed in our CLM is derived from spontaneously occurring endogenous stimuli, rather than from exogenously induced DNA damage by chemotherapy.

The multivariable analysis depicted in the nomogram reveals that the negative association of γH2AX has a bigger impact on OS compared to the positive association of CTLs (CD8). Similarly, γH2AX has a higher influence on RFS than CTLs (CD8). Previously, tumor-infiltrating immune cells were considered as the strongest prognostic parameter in primary CRC as well as CLM [@B9], [@B56]. Our multivariable analysis now indicates that DNA damage is even more relevant for prognosis than tumor-infiltrating immune cells in our dataset. This finding highlights the impact of DNA damage for disease progression and calls for its further understanding as a prognostic marker and as a potential therapeutic target in a clinical setting.

Furthermore, we demonstrate the prognostic relevance of so called "eat-me" signals such as CALR [@B47] in CLM, which has been shown previously in treatment-naïve primary CRC [@B57], [@B58]. The exposure of CALR correlated with a functional type II IFN system (GBP1), CTLs (CD8) and the expression of the DNA sensor cGAS. Additionally, in regards of RFS, CTLs (CD8) are associated with the activation of ER stress response (CALR) and a functional type II IFN system (GBP1) but not with the type I IFN pathway (MxA).

Taken together, translating data from murine models to a clinically applied human setting suggests a key role of DNA damage and sensing, as well as a *bona fide* ICD on the clinical outcome during the course of CLM. Surprisingly, those interactions were already significant on a very limited number of patients, suggesting a high biological impact. Certainly, those findings should be further verified in a larger cohort, as well as in different disease stages and cancer types. In this line, a recently developed positron-emission tomography (PET) imaging agent directed against γH2AX could serve as an attractive approach to monitor current treatment response and clinical outcome [@B59].
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**Marker panel events at the invasive margin and tumor area are correlated with each other**. **(A)** Studydesign. **(B)** Principal component analysis (PCA) of marker panel values at the invasive margin (IM) and tumor area (TU). Each dot represents a CLM sample. PC1 is depicted on the x-axis and PC2 on the y-axis. Percentage of data variance explained by each PC is indicated. Arrows specify vectors for each individual marker at the IM and TU, indicating the impact of the PCs. **(C)** Correlation matrix plots for each individual marker at the IM and TU. Pearson\'s correlation coefficients are indicated in the upper right boxes. Histogram of corresponding value distributions at the IM and TU are shown in the upper left and lower right boxes, respectively. Dashed lines in the lower left boxes represent linear regressions. \*\*\*p\<0.001; CALR: calreticulin. CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; IM: invasive margin; MxA: interferon-induced guanosine triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible gene I; STING: stimulator of interferon genes; TU: tumor area; γH2AX: phosphorylated-histone H2AX.
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###### 

**DNA damage and ER stress response are inversely associated with recurrence‑free survival. (A)** Forest plot indicating hazard ratios (HR; black squares) and corresponding 95% confidence intervals (CI; grey horizontal lines) of marker panel (log~2~ % values) and **(B)** clinical characteristics for RFS. The square size correlates with the range of the 95% CI. The grey vertical line represents the no effect point. Green and red color indicates a statistically significant positive or negative effect, respectively. HR, corresponding 95% CI (within the brackets) and p-values are shown. **(C)** Internal cross-validated adaptive elastic‑net model for RFS is illustrated by a nomogram. A straight upward line to the "Points" axis is drawn for each individual patient clinical characteristic and marker expression (log~2~ % values), following a straight downward line to the "Total Points" axis, the "Linear Predictor" and the corresponding "5-Year Recurrence-free Survival Probability". **(D)** Bootstrap validation of nomogram model over time. The area under the receiver operating characteristic (ROC) curve (specified on the ordinate) is depicted over time (months; specified on the abscissa). The mean (solid blue line), median (dashed blue line), 25% and 75% quantiles (dark grey area), minimum and maximum (light grey area) of the area under the ROC curve are illustrated. **(E)** RFS probability for "high-risk" and "low-risk" groups, which are dichotomized from the nomogram model, is specified on the ordinate. Time (months) is specified on the abscissa. AR: absent response; CALR; calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; CR: complete response; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; IM: invasive margin; KRAS: kirsten rat sarcoma viral oncogene homolog; mTRG: modified tumor regression grading; mut: mutant; MxA: interferon-induced guanosine triphosphate-binding protein MxA; OR: optimal response; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; PD: progressive disease; PR: partial response, partial remission; RIG-I: retinoic acid inducible gene I; SD: stable disease; STING: stimulator of interferon genes; TRG: tumor regression grading; TU: tumor area; wt: wild-type; γH2AX: phosphorylated-histone H2AX.
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###### 

**DNA damage and DNA sensor DDX41 are negatively associated with overall survival. (A)** Forest plot indicating hazard ratios (HR; black squares) and corresponding 95% confidence intervals (CI; grey horizontal lines) of marker panel (log~2~ % values) and **(B)** clinical characteristics for OS. The square size correlates with the range of the 95% CI. The grey vertical line represents the no effect point. Green and red colors indicate a statistically significant positive or negative effect, respectively. HR, corresponding 95% CI (within the brackets) and p-values are shown. **(C)** Internal cross validated adaptive elastic‑net model for OS is illustrated by a nomogram. A straight upward line to the "Points" axis is drawn for each individual patient clinical characteristic and marker expression (log~2~ % values), following a straight downward line to the "Total Points" axis, the "Linear Predictor" and the corresponding "5‑Year Overall Survival Probability". **(D)** Bootstrap validation of nomogram model over time. The area under the receiver operating characteristic (ROC) curve (specified on the ordinate) is depicted over time (months; specified on the abscissa). The mean (solid blue line), median (dashed blue line), 25% and 75% quantiles (dark grey area), minimum and maximum (light grey area) of the area under the ROC curve are illustrated. **(E)** OS probability for "high-risk" and "low-risk" groups, which are dichotomized from the nomogram model, is specified on the ordinate. Time (months) is specified on the abscissa. AR: absent response; CALR; calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; CR: complete response; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; IM: invasive margin; KRAS: kirsten rat sarcoma viral oncogene homolog; mTRG: modified tumor regression grading; mut: mutant; MxA: interferon-induced guanosine triphosphate-binding protein MxA; OR: optimal response; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; PD: progressive disease; PR: partial response, partial remission; RIG-I: retinoic acid inducible gene I; SD: stable disease; STING: stimulator of interferon genes; TRG: tumor regression grading; TU: tumor area; wt: wild-type; γH2AX: phosphorylated-histone H2AX
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![**ER stress response correlates with a functional type II IFN system.** A correlogram of marker panel values is shown. Pearson\'s correlation coefficients (r) for all markers are given in the lower triangle. Colored circles indicate statistically significant correlations, corrected according to the false discovery rate (FDR\<0.05). Size and color intensity of the circles are related to the correlation coefficients. Blue color represents positive and red color negative correlations. CALR: calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; MxA: interferon-induced guanosine triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible gene I; STING: stimulator of interferon genes; γH2AX: phosphorylated-histone H2AX](thnov08p3198g007){#F4}

![**DNA sensors DDX41, STING and p-PKR predict radiographic therapy response.** Comparison of the marker panel between good and poor **(A)** radiographic and **(D)** pathologic responders is indicated by box-and-whisker plots, containing the individual values (Mann-Whitney U test). The bold horizontal line represents the median, the top and bottom of the box illustrate the first and third quartiles, and the whisker represent 1.5 times the interquartile range (IQR). Multivariable logistic regression model (LASSO) for the prediction of **(B)** radiographic and **(E)** pathologic response is illustrated by a receiver operating characteristic (ROC) curve. False positive rate (FPR) is specified at the abscissa and true positive rate (TPR) at the left ordinate. The ROC curve is color-coded according to the threshold values defined on the right ordinate. The black 45° line represents the line of identity. Area under the curve (AUC) and corresponding p-values are indicated. Comparison of the multivariate logistic regression model between good and poor **(C)** radiographic and **(F)** pathologic responders. CALR: calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; MxA: interferon-induced guanosine triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible gene I; STING: stimulator of interferon genes; γH2AX: phosphorylated-histone H2AX](thnov08p3198g008){#F5}

![**DNA damage, ER stress response and DNA sensor DDX41 are associated with therapy response and clinical outcome.** Venn diagram illustrating the overlap between the marker panel and the four different multivariable models (RFS, OS, radiographic and pathologic response). Arrows indicate positive or negative coefficients for each marker. The coefficients of all markers pointed in the same direction (positive or negative) within the four different multivariable models.](thnov08p3198g009){#F6}

###### 

Patient characteristics.

                                                 Total no     
  ---------------------------------------------- ------------ ----------------------
  **Demographics**                               **(n=33)**   
  **Median age ± IQR (years)**                   62 ± 19      
  **Sex**                                                     
  Male                                           17           (52%)
  Female                                         16           (48%)
  **Primary tumor**                                           
  **Tumor location**                                          
  Left                                           26           (12%)
  Right                                          4            (79%)
  Transverse                                     3            (9%)
  **pT stage**                                                
  pT1                                            2            (8%)
  pT2                                            2            (8%)
  pT3                                            20           (76%)
  pT4                                            2            (8%)
  **pN stage**                                                
  pN0                                            11           (39%)
  pN1                                            11           (39%)
  pN2                                            6            (22%)
  **M stage**                                                 
  M0                                             13           (42%)
  M1                                             18           (58%)
  **UICC stage**                                              
  I                                              1            (4%)
  II                                             4            (15%)
  III                                            4            (15%)
  IV                                             18           (66%)
  **Tumor differentiation**                                   
  Well                                           2            (8%)
  Moderate                                       19           (70%)
  Poor                                           6            (22%)
  **Residual Tumor classification**                           
  R0                                             26           (100%)
  **Liver metastases**                                        
  **Metastases timepoint**                                    
  Synchronous                                    19           (58%)
  Metachronous                                   14           (42%)
  **Distribution**                                            
  Unilobular                                     15           (45%)
  Bilobular                                      16           (49%)
  Central                                        2            (6%)
  **Number of lesions**                                       
  Solitary                                       13           (39%)
  Multiple                                       20           (61%)
  **Neoadjuvant chemotherapy**                                
  XELOX                                          19           (58%)
  FOLFIRI                                        4            (12%)
  FOLFOX                                         4            (12%)
  XELIRI                                         2            (6%)
  TOMOX                                          1            (3%)
  Fluorouracil                                   1            (3%)
  Irinotecan                                     1            (3%)
  Raltitrexed + Irinotecan                       1            (3%)
  **Neoadjuvant bevacizumab**                                 
  Yes                                            29           (88%)
  No                                             4            (12%)
  **Neoadjuvant cetuximab**                                   
  Yes                                            2            (6%)
  No                                             31           (94%)
  **Median neoadjuvant cycles ± IQR**            5 ± 3        
  **Radiographic therapy response**                           
  Good response (CR, PR)                         15           (45%)
  Poor response (SD, PD)                         18           (55%)
  **Radiomorphologic therapy response**                       
  Good response (OR, PR)                         20           (60%)
  Poor response (AR)                             13           (40%)
  **Synchronous primary tumor resection**                     
  Yes                                            2            (6%)
  No                                             31           (94%)
  **Histology**                                               
  Adenocarcinoma - Tubular-papillary             27           (82%)
  Adenocarcinoma - Mucinous                      6            (12%)
  **Tumor differentiation**                                   
  Moderate                                       33           (100%)
  **Residual Tumor classification**                           
  R0                                             33           (100%)
  **Pathologic therapy response**                             
  Good response (0-25% viable)                   9            (27%)
  Poor response (≥25% viable)                    24           (73%)
  **Histologic therapy response**                             
  Good response (TRG 1-3)                        4            (12%)
  Poor response (TRG 4-5)                        29           (88%)
  **Modified histologic therapy response**                    
  Good response (mTRG 1-3)                       17           (52%)
  Poor response (mTRG 4-5)                       16           (48%)
  **Mismatch repair status**                                  
  Proficient                                     33           (100%)
  Deficient                                      0            (0%)
  ***KRAS* status**                                           
  Wild-type                                      13           (39%)
  Mutant                                         20           (61%)
  ***BRAF* status**                                           
  Wild-type                                      33           (100%)
  Mutant                                         0            (0%)
  **Median recurrence-free survival (months)**   10           (95% CI 6.66-13.34)
  **Median overall survival (months)**           40           (95% CI 26.50-53.51)

AR: absent response; BRAF: V‑raf murine sarcoma viral oncogene homolog B1; CI: confidence interval; CR: complete response; FOLFIRI: folinic acid, fluorouracil, irinotecan; FOLFOX: folinic acid, fluorouracil, oxaliplatin; IQR: interquartile range; KRAS: kirsten rat sarcoma viral oncogene homolog; Left: descending colon, sigmoid colon or rectum; mTRG: modified tumor regression grading; OR: optimal response; PD: progressive disease; PR: partial response, partial remission; Right: caecum or ascending colon; SD: stable disease; TOMOX: raltitrexed, oxaliplatin; Transverse: transverse colon; TRG: tumor regression grading; UICC: union for international cancer control; XELIRI: capecitabine, irinotecan; XELOX: capecitabine, oxaliplatin.
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